PD47 - PD47: Bladder Cancer: Basic Research & Pathophysiology IV

Podium Presenter(s)

• 

  Timothy Clinton, MD

  Memorial Sloan Kettering Cancer Center

  PDF Slides and Audio
• MD

  Michael Daneshvar
• YH

  Yujiro Hayashi, MD

  Osaka University
• 

  Stanley Malkowicz, MD

  University of Pennsylvania

  PDF Slides and Audio
• KM

  Kathryn Marchetti, MD

  University of Michigan Health System
• CS

  Christopher Silvers
• AS

  Alok Singh
• 

  Debasish Sundi, MD

  Assistant Professor
  Ohio State University
• 

  Leon Telis, MD

  Northwell Health

  PDF Slides and Audio
• GT

  George N. Thalmann
• KW

  Karen Wheeler

Presentations:

• 7:00 AM – 9:00 AM

  PD47-01: GENOMIC DETERMINANTS OF NESTED VARIANT UROTHELIAL CARCINOMA
  Timothy N. Clinton, MD
• 7:00 AM – 9:00 AM

  PD47-02: "Actionable" genomic alterations in chemotherapy resistant muscle-invasive bladder cancer
  Leon Telis, MD
• 7:00 AM – 9:00 AM

  PD47-03: Pre-Clincical Cellular and Genomic Biomarkers of Resistance to Immune Checkpoint Blockade in Urothelial Carcinoma
  Debasish Sundi, MD – Ohio State University
• 7:00 AM – 9:00 AM

  PD47-04: SINGLE CELL RNA-SEQUENCING OF FRESH SUPERFICIAL NON-MUSCLE INVASIVE BLADDER CANCER DEMONSTRATES GENE EXPRESSSION PATHWAY DIFFFERENCES BETWEEN HIGH AND LOW GRADE TUMORS.
  Stanley Bruce Malkowicz, MD
• 7:00 AM – 9:00 AM

  PD47-05: Regulatory T cells play a key role in bladder cancer development
  Karen Wheeler
• 7:00 AM – 9:00 AM

  PD47-06: INTRATUMORAL ADMINISTRATION OF A RECOMBINANT BCG OVEREXPRESSING A STING AGONIST CAUSES INCREASED EXPANSION OF IFN-&[gamma] PRODUCING CD4⁺ T CELLS IN SOLID TUMORS
  Alok Singh
• 7:00 AM – 9:00 AM

  PD47-07: A GENETICALLY MODIFIED BCG THAT OVEREXPRESSES A STING AGONIST SHOWS ENHANCED ANTITUMOR EFFICACY MEDIATED BY AN M1 MACROPHAGE POLARIZATION WITH POTENTIATION OF TRAINED IMMUNITY
  Alok Singh
• 7:00 AM – 9:00 AM

  PD47-08: Urinary exosome cytokine levels correlate with pelvic lymph node inflammation
  Christopher Silvers
• 7:00 AM – 9:00 AM

  PD47-09: Liquid biopsy analysis of TERT promoter mutation in urinary cell-free DNA in patients with urothelial carcinoma.
  Yujiro Hayashi, MD
• 7:00 AM – 9:00 AM

  PD47-10: Multiresolution Application of Artificial Intelligence in Digital Pathology for Prediction of Positive Lymph Nodes from Primary Tumors in Bladder Cancer
  Michael Daneshvar
• 7:00 AM – 9:00 AM

  PD47-11: Rapid Organoid Development, Drug Screening, and Neoadjuvant Chemotherapy Response Prediction for Patients with Locally-Advanced Bladder Cancer
  Kathryn Marchetti, MD
• 7:00 AM – 9:00 AM

  PD47-12: Chacterisation of bladder cancer drug responses in organoids and ex vivo models
  George N. Thalmann